WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Author: search.filters.author.Besisik, Sevgi

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
    (SPRINGER, 2023-01-01) Dal, Mehmet Sinan; Ulu, Bahar Uncu; Uzay, Ant; Akay, Olga Meltem; Besisik, Sevgi; Yenerel, Mustafa Nuri; Celik, Serhat; Kaynar, Leylagul; Yucel, Orhan Kemal; Deveci, Burak; Sonmez, Mehmet; Mehtap, Ozgur; Bekoz, Huseyin Saffet; Sunu, Cenk; Salim, Ozan; Ulas, Turgay; Karti, Sami; Altuntas, Fevzi; Ferhanoglu, Burhan; Tuglular, Tulin Firat
    Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m(2) on day 1, and bendamustine 90 mg/m(2) on days 1-2 of each cycle. Median age at Pola-BR initiation was 55 (19-84). The overall response rate was 47.9\%, including 32.4\% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3-4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.
  • Thumbnail Image
    Item
    Immune modulation as a consequence of SARS-CoV-2 infection
    (FRONTIERS MEDIA SA, 2022-01-01) Gelmez, Metin Yusuf; Oktelik, Fatma Betul; Tahrali, Ilhan; Yilmaz, Vuslat; Kucuksezer, Umut Can; Akdeniz, Nilgun; Cetin, Esin Aktas; Kose, Murat; Cinar, Cigdem; Oguz, Fatma Savran; Besisik, Sevgi; Koksalan, Kaya; Ozdemir, Ozkan; Senkal, Naci; Gul, Ahmet; Tuzun, Erdem; Deniz, Gunnur
    Erroneous immune responses in COVID-19 could have detrimental effects, which makes investigation of immune network underlying COVID-19 pathogenesis a requisite. This study aimed to investigate COVID-19 related alterations within the frame of innate and adaptive immunity. Thirty-four patients clinically diagnosed with mild, moderate and severe COVID-19 disease were enrolled in this study. Decreased ILC1 and increased ILC2 subsets were detected in mild and moderate patients compared to healthy controls. NK cell subsets and cytotoxic capacity of NK cells were decreased in severe patients. Moreover, CD3(+) T cells were reduced in severe patients and a negative correlation was found between CD3(+) T cells and D-dimer levels. Likewise, moderate and severe patients showed diminished CD3(+)CD8(+) T cells. Unlike T and NK cells, plasmablast and plasma cells were elevated in patients and IgG and IgA levels were particularly increased in severe patients. Severe patients also showed elevated serum levels of pro-inflammatory cytokines such as TNF-alpha, IL-6 and IL-8, reduced intracellular IFN-gamma and increased intracellular IL-10 levels. Our findings emphasize that SARS-CoV-2 infection significantly alters immune responses and innate and acquired immunity are differentially modulated in line with the clinical severity of the disease. Elevation of IL-10 levels in NK cells and reduction of CD3(+) and CD8(+) T cells in severe patients might be considered as a protective response against the harmful effect of cytokine storm seen in COVID-19.